[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"varicella-zoster-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:varicella-zoster-virus-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100454517","pharmacokinetics-of-intravenous-acyclovir-in-oncologic-paediatric-patients-100454517",false,"NCT05198570","Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients","Pharmacokinetics of Intravenous Acyclovir in Children Undergoing Hematopoietic Stem Cell Transplantation or High-intensity Antineoplastic Chemotherapy","Inclusion Criteria:\n\n* Patients with Hematological malignancies\n* HSCT recipients who require ACV prophylaxis or treatment for HSV-VZV infection or\n* Children undergoing high-intensity antineoplastic chemotherapy who need ACV treatment.\n* Intravenous or oral ACV dosing\n* Active\u002Favailable a therapeutic drug monitoring (TDM) protocol for ACV\n* Informed consent signed by patient's parents\n\nExclusion Criteria:\n\n* lack of signed informed consent\n* lack of TDM for ACV\n* unavailable patient's demographic characteristics","ALL","6 Months","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","* Herpesvirus infections may be severe in immunocompromised patients, with a high risk of complications and mortality.\n* Recipients of hematopoietic stem cell transplant (HSCT) or patients receiving high-intensity chemotherapy for hematological malignancies are the most vulnerable individuals.\n* Although the worldwide prevalence of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), antiviral prophylaxis in seropositive HSCT recipients has significantly reduced the rate of infection.\n* Acyclovir (ACV) is the first-choice drug for the prophylaxis or the therapy of that kind of infection.\n* Since the beginning, ACV has demonstrated to be characterized by a large interpatient variability, especially in children.\n* Therefore, therapeutic drug monitoring and pharmacokinetic studies may help in optimizing drug in children with malignancies.",[25,26,27,28,29],"Herpesviridae Infections","Herpes Simplex 1","Varicella Zoster Virus Infection","Transplantation Infection","Oncology",[31,32,33,34,35],"Hematopoietic stem cell transplantation","Herpes virus infections","Aciclovir","Children","Pharmacokinetics","RECRUITING","2025-06-02",{"date":39,"type":40},"2025-06-04","ACTUAL",{"date":42,"type":40},"2021-09-15",{"date":44,"type":21},"2026-03-31",{"name":46,"class":47},"University of Pisa","OTHER"]